New hope against a deadly brain infection: large trial tests safer antifungals
NCT ID NCT06666322
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This large platform trial is testing new antifungal drug combinations for cryptococcal meningitis, a severe brain infection that is fatal without treatment and common in people with HIV. The study will enroll 2,000 participants across multiple sites to compare a newer oral drug, oteseconazole, against standard therapy. The goal is to find treatments that are less toxic, more effective, and easier to access worldwide.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Oteseconazole (an oral antifungal drug) compared to standard therapy (liposomal amphotericin B, flucytosine, fluconazole)
What this could lead to
If successful, this could provide safer, more effective, and more accessible treatments for cryptococcal meningitis, potentially lowering the high death rate in low-resource settings.
What could go wrong
This is an early-to-mid-stage platform trial, so results are not guaranteed. New drugs may have unexpected side effects or fail to outperform existing therapies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Infectious Diseases Institute
RECRUITINGKampala, Uganda
Contact Email: •••••@•••••
-
Mbarara University of Science and Technology
RECRUITINGMbarara, Uganda
Contact Phone: •••-•••-•••• Email: •••••@•••••